NCT00099736 - Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant | Biotech Hunter

Enrollment

696

Participants

Timeline

Start Date

May 7, 2003

Primary Completion Date

September 19, 2005

Study Completion Date

September 19, 2005

Conditions

Kidney Transplantation

Interventions

DRUG

FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids

DRUG

FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids

DRUG

MMF 2 g + full-dose Neoral (FDN) + corticosteroids

mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids

Trial Locations (42)

10523

Hawthorne

19102

Philadelphia

22042

Fairfax

23298

Richmond

27599

Chapel Hill

27710

Durham

29425

Charleston

30309

Atlanta

30322

Atlanta

30912

Augusta

33606

Tampa

37212

Nashville

38103

Memphis

43614

Toledo

44106

Cleveland

44195

Cleveland

46202

Indianapolis

48109

Ann Arbor

48202

Detroit

50309

Des Moines

53226

Milwaukee

53792

Madison

55455

Minneapolis

55905

Rochester

60612

Chicago

68198

Omaha

75246

Dallas

77030

Houston

77555

Galveston

78229

San Antonio

80262

Denver

84132

Salt Lake City

85054

Phoenix

90057

Los Angeles

94143

San Francisco

94303

Palo Alto

97232

Portland

06520

New Haven

04102

Portland

02111

Boston

02215

Boston

07039

Livingston